Dear GROUP, Please let me please rephrase that..... I found this on one of my many cancer searches. I was wondering if there is a limit as to how much Liposomal Encapsulated "C" can be ingested each day. Does anyone have any idea how to estimate approximately how much of the finished product it would take, and how often, in order to reach the levels referred to in this report? Thank you, Paul Last resort
First Aid for Advanced Cancer (or for anyone with cancer, at any stage) If the medical profession has just told you that you have a short time to live, or have an "incurable" cancer such as pancreatic, liver, brain or lung cancer, where conventional systemic treatment is at best only palliative, there is a remarkable therapy you can try which is relatively simple and cheap, can be done at home, without side-effects, and which a number of MDs who use it claim has saved the lives of between 60% to 70% of terminal cancer patients, and which at the very least has been shown to halt or control the spread of cancer. This therapy is high dose intravenous vitamin C. Intravenous vitamin C is not the same as oral vitamin C. By giving vitamin C intravenously doctors can achieve a blood saturation that is not at all comparable with that achieved by the oral route. The order of magnitude is something like 200%, as opposed to 2% saturation by the oral route. This very high concentration of vitamin C is critical in terms of achieving a chemotherapeutic, cytotoxic - tumour cell destruction - effect. If it is feasible to have a Hickman line put in the patient, extraordinary doses of vitamin C - anything between 50g to 100g, depending on the malignancy of the cancer, - can be self-administered at home on a daily to weekly basis over a period of months, stepping down or up in frequency according to the individual response. Otherwise this treatment can be administered on an out-patient basis, anywhere in the world. Its effects appear to be enhanced by weekly injections of large doses of vitamin B12, (hydroxycobalamin 1000 micrograms), which forms cobalt ascorbate, another benevolent non-toxic, but tumour cytotoxic, compound, or in combination with vitamin K (specifically vitamin K3, though K1 is also efficacious), and Lipoic Acid, (300mg oral, twice daily.) Lipoic Acid recycles the Vitamin C to keep the cytotoxic dose more constantly in the body for longer periods. Counter indications to this approach are few. However they include anyone with kidney failure, or on dialysis, or with uncommon forms of iron overload. Responsible physicians should also screen for red blood cell glucose-6 phosphate dehydrogenase deficiency, a rare condition whose presence can lead to haemolytic crisis involving red blood cell breakdown. The very large doses should also be built up to gradually over some days to establish good tolerance, starting at 15 grams for 1 or 2 sessions, then to 50 grams and, if necessary, to 100 grams. The exact dose is determined by the individual's plasma saturation by Vitamin C immediately after an infusion. WARNING: To avoid the well-documented Rebound Effect, which can lead to scurvy, this treatment should not be stopped abruptly. Patients should be gradually weaned off it over a period of weeks, or even months, and oral vitamin C therapy should continue indefinitely and on the days in between the IVC infusions. The American Dr Hugh Riordan M.D., who sadly died in 2005, was probably the world expert on this approach. His institute, The Center for the Improvement of Human Functioning, has completed a 10 year research project on high dose intravenous C and cancer. Orthomolecular Medicine News Service, September 22, 2005 Intravenous Vitamin C is Selectively Toxic to Cancer Cells `National Institutes of Health scientists have confirmed the concepts that vitamin C is selectively toxic to cancer cells and that tumor-toxic levels of vitamin C can be attained using intravenous administration. The article, published in the September 12, 2005 issue of the Proceedings of the National Academy of Sciences concluded, "These findings give plausibility to intravenous ascorbic acid in cancer treatment." Scientists associated with the Bio-Communications Research Institute (BRCI) in Wichita, Kansas have published 20 scientific articles on the subject. BCRI researchers first reported in 1995 that vitamin C in sufficient amounts is selectively toxic to tumor cells. The authors concluded that tumor-toxic levels of vitamin C could be achieved only by giving the vitamin intravenously. Subsequent research from BCRI, published in the British Journal of Cancer in 2001, was the first to describe in detail the pharmacokinetics of high doses of intravenous vitamin C. "It is gratifying to have our research on vitamin C and cancer confirmed by scientists at the prestigious National Institutes of Health," said Neil Riordan, Ph.D., BCRI's Research Director. "The findings reinforce our goal and commitment to pursue cutting edge cancer research," added Michael Gonzalez, Ph.D., D.Sc. of the University of Puerto Rico. BCRI's vitamin C research was headed by its founder Hugh D. Riordan, M.D. The research team includes Dr. Xiaolong Meng, Dr. Joseph Casciari, Dr. Nina Mikirova, Dr. Jie Zhong, Dr. James A. Jackson, Dr. Don Davis, Dr. Jorge Miranda, Dr. Michael Gonzalez, Dr. Neil Riordan, and Mr. Paul Taylor.' Dr Riordan also published several successful case histories, including the results of treatment on a late-stage lung cancer patient - now cancer free several years on -, in The Journal of Orthomolecular Medicine. I would recommend anyone interested in this to get in touch with Dr Riordan's clinic, Center For The Improvement Of Human Functioning, to consult them for nutritional strategies against cancer. However, there are a number of other intravenous vitamin C practitioners throughout the world. The International Society for Orthomolecular Medicine can give you the name and address of your nearest orthomolecular physician worldwide. (Or see the Countries List in the Resource Section.) The Doctors and Organisations pages list a few English speaking practitioners, all M.D.s, who also offer excellent alternative and complementary, immunotherapeutic approaches to cancer. For maximum efficacy, they should follow Dr Riordan's treatment protocol, available here, and on request from the Center for the Improvement of Human Functioning: Center For The Improvement Of Human Functioning N. Hillside Avenue, 3100, Wichita, KS 67219, Kansas, U.S.A Tel: 001 316 682 3100 Fax: 001 316 682 5054 Web: www.brightspot.org
